

Richard E. Baltz
Richard.Baltz@aporter.com
+1 202.942.5124
+1 202.942.5999 Fax
555 Twelfth Street, NW
Washington, DC 20004-1206

September 25, 2013

**FOIA CONFIDENTIAL TREATMENT REQUEST
Under 17 CFR §200.83**

**The entity requesting confidential treatment is:
MacroGenics, Inc.
9640 Medical Center Drive
Rockville, MD 20850
Attn: Scott Koenig, M.D., Ph.D.
President and Chief Executive Officer
301-251-5172**

VIA EDGAR SUBMISSION

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attention: Jeffrey P. Riedler

Re: MacroGenics, Inc.
Registration Statement on Form S-1
File No. 333-190994

Ladies and Gentlemen:

On behalf of MacroGenics, Inc. (the "Company"), in order to facilitate your review, we supplementally advise the Staff that the Pricing Committee of the Company's board of directors has approved a price range of \$[**] to \$[**] per share of common stock, based on an approved reverse split of 1-for-[**] shares. Disclosure of the price range and the reverse split will be included in the prospectus contained in the next amendment to the Company's registration statement on Form S-1. The price range, prior to the reverse split, in correlation to the share numbers in the currently filed Form S-1, would be \$[**] to \$[**] per share of common stock.

[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

ARNOLD & PORTER LLP

September 25, 2013

Page 2

If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (202) 942-5124 or by email at richard.baltz@aporter.com. Thank you for your assistance.

Sincerely,

/s/ Richard Baltz

Richard E. Baltz

cc: Office of Freedom of Information and Privacy Act Operations
Securities and Exchange Commission
100 F Street N.E., Mail Stop 2736
Washington, D.C. 20549